Physicians should also carefully explain to the patients the potential benefits and some adverse reactions, such as dyspepsia with dabigatran, associated with these new oral agents and the ...

A new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without leaving ...

The bonds holding the two peptides together can be broken on demand, providing the anticoagulant ingredient with its own on-off switch. This new drug-discovery approach is a potential game-changer ...

These two classes of medications serve completely different purposes. Anticoagulants are used to prevent new and future cases of blood clots that can lead to PE. They may also reduce the size of a ...

Gilead ends $785M Yuhan deal for small-molecule MASH drugs BioWorld Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic ...

a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate ...

Investigators believe that this new anticoagulant, named tecarfarin ... making it susceptible to drug–drug and drug–food interactions, and meaning that it produces highly variable clinical ...

Tom Nolan reviews this week’s research Trials of direct oral anticoagulants for atrial fibrillation have excluded patients with acute ischaemic stroke because of concerns over the risk of haemorrhagic ...

The oral and reversible drug has been uniquely ... developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with ...

Hypertensive patients with stroke who develop atrial fibrillation should be critically and carefully evaluated to be placed on these NOADs for fear of hemorrhagic transformation of the ischemic ...